Phase 1 Study of Single Agent ONX 0912
Currently enrolling
Study Design: Non-randomized, open-label, dose escalation study
Patients: Patients with advanced refractory or recurrent solid tumors
Purpose: To evaluate safety and tolerability including dose limiting toxicity and maximum tolerated dose, as well as to determine the pharmacokinetics of ONX 0912
Locations: Multiple centers throughout the U.S.
Patients: Patients with advanced refractory or recurrent solid tumors
Purpose: To evaluate safety and tolerability including dose limiting toxicity and maximum tolerated dose, as well as to determine the pharmacokinetics of ONX 0912
Locations: Multiple centers throughout the U.S.